文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

肺超声预测COVID-19患者的临床病程与结局

Lung ultrasound predicts clinical course and outcomes in COVID-19 patients.
PubMed 文献 · Intensive Care Med · 2020-08-28
一句话结论连续住院COVID-19患者入院24小时内肺超声评分>18与死亡及需有创机械通气风险升高相关,评分每增加1分死亡风险HR 1.08。

本研究对2020年3月21日至5月4日期间入住Tel Aviv医疗中心的120例连续COVID-19住院患者在入院24小时内进行完整肺超声评估,采用0(最佳)至36(最差)评分,临床恶化时复查。基线总LUS评分中位数15(IQR 7-20),80例(67%)为0-18分,40例(33%)为19-36分;多数患者至少一个区域存在斑片状胸膜增厚(100例,83%)或斑片状胸膜下实变(93例,78%)。胸膜增厚、胸膜下实变患病率及总LUS评分均与入院时病情严重程度相关;临床恶化与随访LUS评分升高相关(p=0.0009),主要因前部肺段通气丧失。LUS评分最佳截断值为18(敏感度62%,特异度74%);基线LUS评分>18者死亡及需要有创机械通气均较0-18分者增加。未校正死亡HR为每分1.08 [1.02-1.16],p=0.008;复合终点(死亡或需有创机械通气)未校正HR为每分1.12 [1.05-1.2],p=0.0008。作者认为常规使用LUS可能指导患者管理策略及容量激增时的资源分配。

要点

  • 连续120例COVID-19住院患者入院24小时内行完整肺超声,基线总LUS评分中位数15(IQR 7-20)。
  • 基线LUS评分>18者死亡及需有创机械通气均较0-18分者增加,最佳截断值18(敏感度62%,特异度74%)。
  • 未校正死亡HR为LUS评分每分1.08 [1.02-1.16],p=0.008;复合终点未校正HR每分1.12 [1.05-1.2],p=0.0008。
  • 临床恶化与随访LUS评分升高相关(p=0.0009),主要因前部肺段通气丧失。
  • 多数患者至少一个区域存在斑片状胸膜增厚(83%)或斑片状胸膜下实变(78%),且与入院病情严重程度相关。

适用人群与场景

  • 2020年3月21日至5月4日期间因COVID-19入住Tel Aviv医疗中心的120例连续住院患者,涵盖所有临床分级。
  • 入院24小时内接受完整肺超声评估,临床恶化时进行第二次检查。

诊断标准与关键阈值

  • 肺超声评分范围0(最佳)至36(最差),对每位患者进行评分。
  • 预测临床结局的最佳截断值为LUS评分18(敏感度62%,特异度74%)。

研究设计与关键结果

  • 研究类型为对连续住院COVID-19患者的前瞻性肺超声评估(原文未明确写前瞻性,但描述为连续患者入院24小时内行完整LUS并临床恶化复查),样本量120例,单中心(Tel Aviv医疗中心)。
  • 基线总LUS评分中位数15,IQR [7-20];基线LUS评分0-18者80例(67%),19-36者40例(33%)。
  • 至少一个区域存在斑片状胸膜增厚者100例(83%),斑片状胸膜下实变者93例(78%)。
  • 胸膜增厚、胸膜下实变患病率及总LUS评分均与入院时病情严重程度相关。
  • 临床恶化与随访LUS评分升高相关(p=0.0009),主要因前部肺段通气丧失。
  • 基线LUS评分>18者死亡及需有创机械通气均较基线LUS评分0-18者增加。
  • 未校正死亡HR为LUS评分每分1.08 [1.02-1.16],p=0.008;未校正复合终点(死亡或需有创机械通气)HR为每分1.12 [1.05-1.2],p=0.0008。

证据类型、等级与局限

  • 证据类型:对连续住院COVID-19患者进行肺超声评估的临床研究(原文未明确写研究设计类型,如RCT或队列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,常规使用LUS可能指导患者管理策略,以及在容量激增时指导资源分配。
  • 基线LUS评分与最终需有创机械通气及死亡相关,可用于风险分层。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Information regarding the use of lung ultrasound (LUS) in patients with Coronavirus disease 2019 (COVID-19) is quickly accumulating, but its use for risk stratification and outcome prediction has yet to be described. We performed the first systematic and comprehensive LUS evaluation of consecutive patients hospitalized with COVID-19 infection, in order to describe LUS findings and their association with clinical course and outcome.

METHODS: Between 21/03/2020 and 04/05/2020, 120 consecutive patients admitted to the Tel Aviv Medical Center due to COVID-19, underwent complete LUS within 24 h of admission. A second exam was performed in case of clinical deterioration. LUS score of 0 (best)-36 (worst) was assigned to each patient. LUS findings were compared with clinical data.

RESULTS: The median baseline total LUS score was 15, IQR [7-20]. Baseline LUS score was 0-18 in 80 (67%) patients, and 19-36 in 40 (33%) patients. The majority had patchy pleural thickening (n = 100; 83%), or patchy subpleural consolidations (n = 93; 78%) in at least one zone. The prevalence of pleural thickening, subpleural consolidations and the total LUS score were all correlated with severity of illness on admission. Clinical deterioration was associated with increased follow-up LUS scores (p = 0.0009), mostly due to loss of aeration in anterior lung segments. The optimal cutoff point for LUS score was 18 (sensitivity = 62%, specificity = 74%). Both mortality and need for invasive mechanical ventilation were increased with baseline LUS score > 18 compared to baseline LUS score 0-18. Unadjusted hazard ratio of death for LUS score was 1.08 per point [1.02-1.16], p = 0.008; Unadjusted hazard ratio of the composite endpoint (death or need for invasive mechanical ventilation) for LUS score was 1.12 per point [1.05-1.2], p = 0.0008.

CONCLUSION: Hospitalized patients with COVID-19, at all clinical grades, present with pathological LUS findings. Baseline LUS score strongly correlates with the eventual need for invasive mechanical ventilation and is a strong predictor of mortality. Routine use of LUS may guide patients' management strategies, as well as resource allocation in case of surge capacity.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lichter Y, Topilsky Y, Taieb P, et al. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. Intensive Care Med. 2020. PMID: 32860069. doi:10.1007/s00134-020-06212-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。